title: Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients.
abstract: Defibrotide, an antithrombotic drug, was previously shown to activate fibrinolysis. In order to elucidate the relationship between defibrotide treatment and fibrinolysis, ten atherosclerotic patients were given 1200 mg/day defibrotide intravenously for 7 days and then 400 mg/day intramuscularly for another 20 days. t-PA antigen assessed before and after venous occlusion was not affected by the treatment. Tissue PAI activity significantly decreased and t-PA activity, measured after venous occlusion, increased after 8 and 28 days of treatment; both these changes disappeared after defibrotide was discontinued. No particular side effects were detected throughout the investigation. The study suggests that defibrotide increases t-PA activity by reducing PAI activity.
authors.affiliation: Instituto Ia Clinica Medica, Universita La Sapienza, Roma, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Violi
authors.forename: D
authors.initials: D
authors.lastname: Ferro
authors.forename: C
authors.initials: C
authors.lastname: Alessandri
authors.forename: C
authors.initials: C
authors.lastname: Quintarelli
authors.forename: M
authors.initials: M
authors.lastname: Saliola
authors.forename: F
authors.initials: F
authors.lastname: Balsano
mesh_terms: D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D001780:Blood Coagulation Tests; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage*; D010959:Tissue Plasminogen Activator / Q000037:antagonists & inhibitors*
chemical_list: D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D010959:Tissue Plasminogen Activator